KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EPS (Weighted Average and Diluted): 2010-2024

Historic EPS (Weighted Average and Diluted) for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to -$3.60.

  • Emergent BioSolutions' EPS (Weighted Average and Diluted) fell 55.83% to $0.91 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.31, marking a year-over-year increase of 132.51%. This contributed to the annual value of -$3.60 for FY2024, which is 75.76% up from last year.
  • As of FY2024, Emergent BioSolutions' EPS (Weighted Average and Diluted) stood at -$3.60, which was up 75.76% from -$14.85 recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' EPS (Weighted Average and Diluted) ranged from a high of $5.68 in FY2020 and a low of -$14.85 during FY2023.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$4.22 (2022), whereas its average is -$7.56.
  • As far as peak fluctuations go, Emergent BioSolutions' EPS (Weighted Average and Diluted) skyrocketed by 446.15% in 2020, and later slumped by 251.90% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' EPS (Weighted Average and Diluted) stood at $5.68 in 2020, then dropped by 28.52% to $4.06 in 2021, then crashed by 203.94% to -$4.22 in 2022, then crashed by 251.90% to -$14.85 in 2023, then spiked by 75.76% to -$3.60 in 2024.